Millions of Americans take a daily blood-pressure pill alongside vitamins, herbal extracts, or mineral supplements without a second thought. Federal health agencies and published clinical research tell a different story: certain common supplements can sharply reduce the effectiveness of heart medications or push blood pressure in the wrong direction. The FDA has warned that combining medications with supplements can trigger dangerous changes in blood pressure and heart rate, and the agency does not review supplements for safety or effectiveness before they reach store shelves. A clinical trial in healthy volunteers found that green tea greatly reduced plasma concentrations of the beta-blocker nadolol, raising the risk of lost blood-pressure control depending on when the tea was consumed relative to the dose.
How Green Tea and Nadolol Timing Shifts Blood-Pressure Control
The clearest example of a supplement undermining a heart drug comes from a pharmacokinetic study published in Clinical Pharmacology and Therapeutics. Researchers found that green tea ingestion greatly reduces plasma concentrations of nadolol in healthy subjects. Nadolol is a beta-blocker prescribed to lower blood pressure and manage certain cardiac conditions. When green tea was consumed alongside the drug, the body absorbed far less of it, meaning the medication could not do its job.
A follow-up study published in the British Journal of Clinical Pharmacology examined how the timing of green tea relative to nadolol dosing changes the drug’s pharmacokinetics. That research, available through PubMed Central, showed that a single serving of green tea taken close to the nadolol dose altered how much of the drug reached the bloodstream. The mechanism appears to involve organic anion transporting polypeptides in the gut, which green tea catechins can inhibit, blocking the drug from being absorbed properly.
The practical question for patients is whether separating green tea intake from nadolol dosing by several hours can preserve the drug’s effectiveness. The pharmacokinetic data suggest that timing matters, but no large-scale trial has yet confirmed a specific safe window or measured the resulting change in systolic blood pressure over weeks of real-world use. Patients taking nadolol who also drink green tea daily face a measurable risk that their blood pressure is not as well controlled as their prescriber assumes.
St. John’s Wort, Licorice, and Potassium Create Separate Hazards
Green tea is not the only supplement that interferes with cardiovascular drugs. St. John’s wort, widely sold as a mood supplement, is classified by the NIH National Center for Complementary and Integrative Health as high-risk for herb–drug interactions because it activates CYP enzymes and P-glycoprotein transporters in the gut and liver. A clinical study published in Clinical Pharmacology and Therapeutics demonstrated that St. John’s wort reduces the oral bioavailability of talinolol, a cardiovascular drug that relies on P-glycoprotein transport for absorption. The result: less drug reaches the bloodstream, and therapeutic failure becomes more likely.
Licorice root presents the opposite problem. Rather than blunting a drug’s effect, licorice can raise blood pressure on its own. The NIH National Center for Complementary and Integrative Health lists licorice root as a supplement that may raise blood pressure, which directly counteracts the goal of antihypertensive therapy. A patient faithfully taking a prescribed blood-pressure pill while also consuming licorice supplements could find that their readings stay stubbornly high, with neither patient nor doctor suspecting the supplement as the cause.
Potassium supplements add yet another layer of risk, particularly for people on ACE inhibitors or potassium-sparing diuretics. The NIH Office of Dietary Supplements documents that potassium supplements can cause hyperkalemia when taken alongside these medications. Hyperkalemia, or dangerously elevated blood potassium, can trigger cardiac arrhythmias and, in severe cases, cardiac arrest. Patients sometimes begin potassium supplements after reading about electrolyte health without realizing the interaction with their existing prescriptions.
Grapefruit juice, while not a capsule supplement, behaves like one in terms of drug interactions. The FDA warns that grapefruit juice can alter exposure for certain medications, including nifedipine products used to treat high blood pressure. The mechanism involves grapefruit compounds blocking an enzyme in the intestinal wall, allowing more of the drug to enter the bloodstream than intended. The result can be an excessive drop in blood pressure, dizziness, or fainting.
Gaps in Reporting and What Patients Should Do Next
Despite clear pharmacology and scattered clinical reports, most of these interactions rarely appear in routine clinical documentation. Electronic medical records typically prompt prescribers to reconcile prescription drugs, but over-the-counter supplements are often recorded haphazardly, if at all. Patients may list a multivitamin but omit herbal capsules, teas, or powders they view as “natural” and therefore harmless. When blood pressure readings drift upward or downward unexpectedly, the chart may not capture that a new supplement has entered the mix.
Regulatory gaps compound the problem. Prescription medications are tested in formal trials that document expected interactions with other drugs. By contrast, dietary supplements reach the market without pre-approval for safety or efficacy. As the FDA notes, manufacturers are largely responsible for ensuring that their products are safe and properly labeled, and post-market surveillance depends heavily on voluntary reporting. That makes it difficult for clinicians and patients to know in advance which combinations of pills, capsules, and beverages will prove hazardous.
For people living with hypertension or heart disease, the safest approach is to treat supplements with the same seriousness as prescription drugs. Patients should bring all products they take-bottles of vitamins, herbal extracts, electrolyte powders, and even favored teas-to medical appointments and ask explicitly about possible interactions with their blood-pressure medications. Pharmacists are well positioned to flag known problems, such as green tea with nadolol, St. John’s wort with P-glycoprotein–dependent drugs, licorice with hypertension, or potassium with ACE inhibitors and potassium-sparing diuretics.
Clinicians, for their part, can reduce risk by asking targeted questions instead of relying on generic intake forms. Rather than “Do you take any supplements?”, more specific prompts-“Do you drink green tea every day?”, “Do you use herbal products for mood or energy?”, “Do you take any powders or capsules for electrolytes or muscle cramps?”-are more likely to uncover relevant products. When blood pressure control suddenly worsens or a patient reports dizziness or palpitations, a careful review of recent supplement changes should be part of the diagnostic workup.
Consumers who prefer to continue using supplements do not necessarily need to abandon them altogether, but they should be prepared to adjust timing, dose, or product choice. In some cases, such as the green tea–nadolol interaction, separating intake by several hours may reduce risk, though the optimal window has not been established in large outcome trials. In others-like licorice in someone with difficult-to-control hypertension, or potassium capsules in a person already on a potassium-sparing drug-the safest option may be to stop the supplement entirely under medical guidance.
Ultimately, the science around supplements and heart medications is still evolving, but the existing evidence points toward a simple message: “natural” does not mean neutral. Until reporting systems and regulations catch up, patients and clinicians will need to close the information gap themselves, treating every capsule, extract, and “healthy” beverage as a potential variable in blood-pressure control rather than an afterthought.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
